{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T17:51:57Z","timestamp":1785433917719,"version":"3.56.0"},"reference-count":111,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012190","name":"Ministry of Science and Higher Education of the Russian Federation","doi-asserted-by":"crossref","award":["075-15-2025-519"],"award-info":[{"award-number":["075-15-2025-519"]}],"id":[{"id":"10.13039\/501100012190","id-type":"DOI","asserted-by":"crossref"}]},{"award":["075-15-2025-519"],"award-info":[{"award-number":["075-15-2025-519"]}],"id":[{"id":"https:\/\/ror.org\/00ghqgy32","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Cancer remains the leading cause of death in domestic dogs. Conventional therapeutic approaches, including surgery, chemotherapy, and radiotherapy, frequently fail to achieve sustained remission or stabilization. Oncolytic virotherapy, a rapidly advancing therapeutic modality in human oncology, is emerging as a novel strategy in veterinary medicine. This systematic review summarizes current knowledge on the application of oncolytic viruses (OVs) in canine cancer treatment, focusing on their mechanisms of action, safety profiles, and clinical efficacy. We evaluate diverse OV platforms, including myxoma virus, reovirus, vesicular stomatitis virus, canine adenoviruses, vaccinia virus, Sendai virus, and Newcastle disease virus, across preclinical and clinical studies in dogs with various malignancies. While several OVs have demonstrated favorable tolerability and modest antitumor activity, key challenges such as pre-existing immunity, optimization of dosing regimens, and rational combination strategies remain to be addressed. This review emphasizes the translational significance of canine studies for both veterinary and human oncology, underscoring the critical need for rigorously designed clinical trials to refine virotherapy protocols and expand therapeutic options for canine cancer patients.<\/jats:p>","DOI":"10.3390\/v18050518","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T10:47:28Z","timestamp":1777546048000},"page":"518","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncolytic Viruses for Cancer Therapy in Dogs"],"prefix":"10.3390","volume":"18","author":[{"given":"Daria O.","family":"Neymysheva","sequence":"first","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"},{"name":"Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina V.","family":"Ilyinskaya","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"},{"name":"Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8158-4519","authenticated-orcid":false,"given":"Viktoria A.","family":"Sarkisova","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"},{"name":"Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"},{"name":"Faculty of Biology, Lomonosov Moscow State University, Moscow 119234, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena A.","family":"Mukhina","sequence":"additional","affiliation":[{"name":"Institute of Immunology Federal Medical-Biological Agency of Russia, Moscow 115522, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia A.","family":"Romanen-kova","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow 119048, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-2908","authenticated-orcid":false,"given":"Peter M.","family":"Chumakov","sequence":"additional","affiliation":[{"name":"Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"},{"name":"Center for Precision Genetic Technologies for Medicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/aac2.12046","article-title":"Increased risk of cancer in dogs and humans: A consequence of recent extension of lifespan beyond evolutionarily-determined limitations?","volume":"3","author":"Sarver","year":"2022","journal-title":"Aging Cancer"},{"key":"ref_2","first-page":"150","article-title":"Mechanisms of Drug Resistance in Veterinary Oncology-A Review with an Emphasis on Canine Lymphoma","volume":"2","author":"Zandvliet","year":"2015","journal-title":"Vet. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Stephens, T. (2019). The Use of Chemotherapy to Prolong the Life of Dogs Suffering from Cancer: The Ethical Dilemma. Animals, 9.","DOI":"10.3390\/ani9070441"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Klingemann, H. (2021). Immunotherapy for Dogs: Still Running Behind Humans. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.665784"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sinkovics, J.G., and Horvath, J.C. (2008). Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch. Immunol. Ther. Exp., 56.","DOI":"10.1007\/s00005-008-0047-9"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47\u0394: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the World First Oncolytic Virus Medicine and its Update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: The Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Ferrucci, P.F., Pala, L., Conforti, F., and Cocorocchio, E. (2021). Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers, 13.","DOI":"10.3390\/cancers13061383"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1200\/JCO.20.03246","article-title":"Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma","volume":"39","author":"Andtbacka","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Lin, D., Shen, Y., and Liang, T. (2023). Oncolytic virotherapy: Basic principles, recent advances and future directions. Signal Transduct. Target. Ther., 8.","DOI":"10.1038\/s41392-023-01407-6"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Matveeva, O.V., and Chumakov, P.M. (2018). Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses. Rev. Med. Virol., 28.","DOI":"10.1002\/rmv.2008"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Kooti, W., Esmaeili Gouvarchin Ghaleh, H., Farzanehpour, M., Dorostkar, R., Jalali Kondori, B., and Bolandian, M. (2021). Oncolytic Viruses and Cancer, Do You Know the Main Mechanism?. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.761015"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/1759-7714.13043","article-title":"Updates to the antitumor mechanism of oncolytic virus","volume":"10","author":"Bai","year":"2019","journal-title":"Thorac. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Vitiello, G.A.F., Ferreira, W.A.S., Cordeiro de Lima, V.C., and Medina, T.D.S. (2021). Antiviral Responses in Cancer: Boosting Antitumor Immunity Through Activation of Interferon Pathway in the Tumor Microenvironment. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.782852"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Spiesschaert, B., McFadden, G., Hermans, K., Nauwynck, H., and Van de Walle, G.R. (2011). The current status and future directions of myxoma virus, a master in immune evasion. Vet. Res., 42.","DOI":"10.1186\/1297-9716-42-76"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1172\/JCI121323","article-title":"Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival","volume":"129","author":"Kellish","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/1078-0432.CCR-16-0143","article-title":"Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma","volume":"22","author":"Lawson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_19","unstructured":"(2026, April 01). Phase 2 Study of Intravenous Administration of Reovirus Serotype 3-Dearing Strain (REOLYSIN\u00ae) in Combination with Paclitaxel and Carboplatin in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer Who Have KRAS or EGFR Activated Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00861627."},{"key":"ref_20","unstructured":"PrEcog, LLC. (2026, April 01). A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with Anti-PD-L1 Avelumab and Paclitaxel-BRACELET-1 Study, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04215146."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ahmed, M.M., Okesanya, O.J., Ukoaka, B.M., Ibrahim, A.M., and Lucero-Prisno, D.E. (2024). Vesicular Stomatitis Virus: Insights into Pathogenesis, Immune Evasion, and Technological Innovations in Oncolytic and Vaccine Development. Viruses, 16.","DOI":"10.3390\/v16121933"},{"key":"ref_22","unstructured":"National Cancer Institute (NCI) (2026, April 01). Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic\/Dendritic Cell Neoplasms, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03017820."},{"key":"ref_23","unstructured":"Mayo Clinic (2026, April 01). Phase 1\u20132 Trial of Systemically Administered VSV-IFN\u03b2-NIS in Combination with Checkpoint Inhibitor Therapy in Patients with Selected Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03647163."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2460\/javma.1980.177.03.234","article-title":"Evaluation of a canine adenovirus type 2 strain as a replacement for infectious canine hepatitis vaccine","volume":"177","author":"Bass","year":"1980","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"10639","DOI":"10.1128\/JVI.74.22.10639-10649.2000","article-title":"Canine adenovirus type 2 attachment and internalization: Coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway","volume":"74","author":"Soudais","year":"2000","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Zhu, Y., Xu, J., Lian, S., Zhang, R., Hou, J., Wang, M., and Yan, X. (2022). Difference Analysis Between Canine Adenovirus Types 1 and 2. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.854876"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: Past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_28","unstructured":"(2026, April 01). A First-in-Human, Phase I, Multi-Center, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06910657."},{"key":"ref_29","unstructured":"(2026, April 01). Exploratory Study of Oncolytic Vaccinia VIrus-Delivered Targeted CD19 In Vivo CAR-T\/M Therapy for Refractory\/Relapsed B-Cell Lymphoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT07398963."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1349-7006.2008.00964.x","article-title":"Non-transmissible Sendai virus encoding granulocyte macrophage colony-stimulating factor is a novel and potent vector system for producing autologous tumor vaccines","volume":"99","author":"Inoue","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/cgt.2017.15","article-title":"Phase I\/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients","volume":"24","author":"Fujita","year":"2017","journal-title":"Cancer Gene Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Sakura, K., Kuroyama, M., Shintani, Y., Funaki, S., Atagi, S., Kadota, Y., Kuribayashi, K., Kijima, T., Nakano, T., and Nakajima, T. (2024). Dose-escalation, tolerability, and efficacy of intratumoral and subcutaneous injection of hemagglutinating virus of Japan envelope (HVJ-E) against chemotherapy-resistant malignant pleural mesothelioma: A clinical trial. Cancer Immunol. Immunother., 73.","DOI":"10.1007\/s00262-024-03815-1"},{"key":"ref_33","unstructured":"(2026, April 01). A Phase I Double-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Intranasal Sendai Virus Vectored Respiratory Syncytial Virus (SeVRSV) Vaccine in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03473002."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.virusres.2014.02.016","article-title":"Newcastle disease virus: Current status and our understanding","volume":"184","author":"Ganar","year":"2014","journal-title":"Virus Res."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2016). Fifty Years of Clinical Application of Newcastle Disease Virus: Time to Celebrate!. Biomedicines, 4.","DOI":"10.3390\/biomedicines4030016"},{"key":"ref_36","first-page":"49","article-title":"Therapeutic potential of oncolytic Newcastle disease virus: A critical review","volume":"4","author":"Tayeb","year":"2015","journal-title":"Oncolytic Virotherapy"},{"key":"ref_37","unstructured":"(2026, April 01). Phase II: Safety and Primary Efficacy of Clinical Application of Newcastle Disease Virus for the Treatment of Patients Resistant to All Conventional Modalities, Available online: https:\/\/clinicaltrials.gov\/study\/NCT00348842."},{"key":"ref_38","first-page":"619","article-title":"Attenuated veterinary virus vaccine for the treatment of cancer","volume":"17","author":"Csatary","year":"1993","journal-title":"Cancer Detect. Prev."},{"key":"ref_39","first-page":"947","article-title":"Tumor response and 4 year survival-data of patients with advanced renal-cell carcinoma treated with autologous tumor vaccine and subcutaneous R-IL-2 and IFN-alpha(2b)","volume":"6","author":"Pomer","year":"1995","journal-title":"Int. J. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Enow, J.A., Lopes, A.M., Abrantes, J., Esteves, P.J., and Rahman, M.M. (2025). The Role of Myxoma Virus Immune Modulators and Host Range Factors in Pathogenesis and Species Leaping. Viruses, 17.","DOI":"10.3390\/v17081145"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Schin, A.M., Diesterbeck, U.S., and Moss, B. (2021). Insights into the Organization of the Poxvirus Multicomponent Entry-Fusion Complex from Proximity Analyses in Living Infected Cells. J. Virol., 95.","DOI":"10.1128\/JVI.00852-21"},{"key":"ref_42","unstructured":"Shaban, M. (2006). Myxoma Virus Oncolytic Activity in a Murine Melanoma Model: An In Vitro to In Vivo Study. [Ph.D. Thesis, Faculty of Graduate Studies, University of Western Ontario]."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"MacNeill, A.L., Weishaar, K.M., Seguin, B., and Powers, B.E. (2018). Safety of an Oncolytic Myxoma Virus in Dogs with Soft Tissue Sarcoma. Viruses, 10.","DOI":"10.3390\/v10080398"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2460\/ajvr.73.8.1252","article-title":"Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene","volume":"73","author":"Urbasic","year":"2012","journal-title":"Am. J. Vet. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1128\/JVI.72.10.7830-7839.1998","article-title":"Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus","volume":"72","author":"Gelfi","year":"1998","journal-title":"J. Virol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ashton, L.V., Weishaar, K.M., S\u00e9guin, B., and MacNeill, A.L. (2023). Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma. Biomedicines, 11.","DOI":"10.20944\/preprints202307.1208.v1"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cloquell, A., Mateo, I., Gambera, S., Pumarola, M., Alemany, R., Garc\u00eda-Castro, J., and Peris\u00e9-Barrios, A.J. (2022). Systemic cellular viroimmunotherapy for canine high-grade gliomas. J. Immunother. Cancer, 10.","DOI":"10.1136\/jitc-2022-005669"},{"key":"ref_48","first-page":"646","article-title":"Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: A comprehensive review","volume":"20","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Stawowczyk, M., Ye, Y., and Chen, N.G. (2025). Vaccinia Virus-A Swiss Army Knife Against Cancer. Cancers, 17.","DOI":"10.20944\/preprints202506.1045.v1"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/jid.2014.330","article-title":"Vaccinia virus binds to the scavenger receptor MARCO on the surface of keratinocytes","volume":"135","author":"MacLeod","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.omto.2023.07.005","article-title":"Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors","volume":"30","author":"Laloy","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omto.2020.08.020","article-title":"Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer","volume":"19","author":"Foloppe","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.omto.2019.03.005","article-title":"The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism","volume":"14","author":"Foloppe","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"B\u00e9guin, J., Nourtier, V., Gantzer, M., Cochin, S., Foloppe, J., Balloul, J.M., Laloy, E., Tierny, D., Klonjkowski, B., and Quemeneur, E. (2020). Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs. BMC Vet. Res., 16.","DOI":"10.1186\/s12917-020-02524-y"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s40588-019-00121-8","article-title":"Reovirus: Friend and Foe","volume":"6","author":"Eledge","year":"2019","journal-title":"Curr. Clin. Microbiol. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1292\/jvms.13-0472","article-title":"Seroepidemiology of reovirus in healthy dogs in six prefectures in Japan","volume":"76","author":"Hwang","year":"2014","journal-title":"J. Vet. Med. Sci.\/Jpn. Soc. Vet. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S0092-8674(01)00231-8","article-title":"Junction adhesion molecule is a receptor for reovirus","volume":"104","author":"Barton","year":"2001","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.1128\/JVI.79.13.7967-7978.2005","article-title":"Junctional adhesion molecule a serves as a receptor for prototype and field-isolate strains of mammalian reovirus","volume":"79","author":"Campbell","year":"2005","journal-title":"J. Virol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.addr.2005.01.005","article-title":"The JAM family of proteins","volume":"57","author":"Mandell","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1242\/jcs.01661","article-title":"Expression of junctional adhesion molecule-A prevents spontaneous and random motility","volume":"118","author":"Bazzoni","year":"2005","journal-title":"J. Cell Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1074\/jbc.M004680200","article-title":"Utilization of sialic acid as a coreceptor enhances reovirus attachment by multistep adhesion strengthening","volume":"276","author":"Barton","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/mmt.15.13","article-title":"Oncolytics Biotech(\u00ae) Inc.: REOLYSIN(\u00ae) for melanoma therapy","volume":"2","author":"Thompson","year":"2015","journal-title":"Melanoma Manag."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hwang, C.C., Umeki, S., Kubo, M., Hayashi, T., Shimoda, H., Mochizuki, M., Maeda, K., Baba, K., Hiraoka, H., and Coffey, M. (2013). Oncolytic reovirus in canine mast cell tumor. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073555"},{"key":"ref_64","first-page":"21","article-title":"Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor","volume":"80","author":"Igase","year":"2016","journal-title":"Can. J. Vet. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/vco.12124","article-title":"The effects of oncolytic reovirus in canine lymphoma cell lines","volume":"14","author":"Hwang","year":"2016","journal-title":"Vet. Comp. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1292\/jvms.14-0570","article-title":"The oncolytic effects of reovirus in canine solid tumor cell lines","volume":"77","author":"Igase","year":"2015","journal-title":"J. Vet. Med. Sci.\/Jpn. Soc. Vet. Sci."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/vco.12361","article-title":"Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours","volume":"16","author":"Hwang","year":"2018","journal-title":"Vet. Comp. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.omto.2019.08.003","article-title":"Combination Therapy with Reovirus and ATM Inhibitor Enhances Cell Death and Virus Replication in Canine Melanoma","volume":"15","author":"Igase","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4269\/ajtmh.1966.15.244","article-title":"Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV)","volume":"15","author":"Johnson","year":"1966","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.virusres.2013.06.003","article-title":"Understanding and altering cell tropism of vesicular stomatitis virus","volume":"176","author":"Hastie","year":"2013","journal-title":"Virus Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1099\/jgv.0.000980","article-title":"Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: A 5-year update","volume":"98","author":"Felt","year":"2017","journal-title":"J. Gen. Virol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Bennani, N.N., Cook, J., Geyer, S.M., Ginos, B.F., Zhang, L., Munoz, J., Broski, S., Russell, S., Peng, K.-W., and Lacy, M. (2023). Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients with Relapsed or Refractory Multiple Myeloma, Lymphomas, or Histiocytic\/Dendritic Cell Neoplasms. Blood, 142.","DOI":"10.1182\/blood-2023-190664"},{"key":"ref_73","first-page":"174","article-title":"Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. Human gene therapy","volume":"24","author":"LeBlanc","year":"2013","journal-title":"Clin. Dev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/1535-7163.MCT-17-0432","article-title":"Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer","volume":"17","author":"Naik","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/vco.12677","article-title":"Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats","volume":"19","author":"LeBlanc","year":"2021","journal-title":"Vet. Comp. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Makielski, K.M., Sarver, A.L., Henson, M.S., Stuebner, K.M., Borgatti, A., Suksanpaisan, L., Preusser, C., Tabaran, A.-F., Cornax, I., and O\u2019Sullivan, M.G. (2023). Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma. Mol. Ther. Oncolytics, 31.","DOI":"10.1016\/j.omto.2023.100736"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Liu, Z., Li, L., Wu, J., Zhang, H., Zhang, H., Lei, T., and Xu, B. (2021). Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.707290"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ramamoorthy, S., Garg, S., Mishra, B., Radotra, B.D., and Saikia, U.N. (2023). Coxsackievirus and Adenovirus Receptor (CAR) Expression in Autopsy Tissues: Organ-Specific Patterns and Clinical Significance. Cureus, 15.","DOI":"10.7759\/cureus.37138"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.gt.3301775","article-title":"Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas","volume":"9","author":"Zeimet","year":"2002","journal-title":"Gene Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/107155760200900310","article-title":"Adenovirus-mediated thymidine kinase gene therapy for recurrent ovarian cancer: Expression of coxsackie-adenovirus receptor and integrins alphavbeta3 and alphavbeta5","volume":"9","author":"Hasenburg","year":"2002","journal-title":"J. Soc. Gynecol. Investig."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10238-005-0076-1","article-title":"The Coxsackie-adenovirus receptor has elevated expression in human breast cancer","volume":"5","author":"Martin","year":"2005","journal-title":"Clin. Exp. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10735-006-9055-4","article-title":"Coxsackievirus and adenovirus receptor expression in non-malignant lung tissues and clinical lung cancers","volume":"37","author":"Wang","year":"2006","journal-title":"J. Mol. Histol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1158\/0008-5472.CAN-04-1490","article-title":"A novel role for the coxsackie adenovirus receptor in mediating tumor formation by lung cancer cells","volume":"64","author":"Qin","year":"2004","journal-title":"Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.pcan.4500611","article-title":"Coxsackie B and adenovirus receptor, integrin and major histocompatibility complex class I expression in human prostate cancer cell lines: Implications for gene therapy strategies","volume":"6","author":"Pandha","year":"2003","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Uotani, K., Tazawa, H., Hasei, J., Fujiwara, T., Yoshida, A., Yamakawa, Y., Omori, T., Sugiu, K., Komatsubara, T., and Kondo, H. (2024). Fluorescence-guided assessment of bone and soft-tissue sarcomas for predicting the efficacy of telomerase-specific oncolytic adenovirus. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0298292"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.2460\/ajvr.1988.49.09.1460","article-title":"Serum antibody response to canine parvovirus, canine adenovirus-1, and canine distemper virus in dogs with known status of immunization: Study of dogs in Sweden","volume":"49","author":"Olson","year":"1988","journal-title":"Am. J. Vet. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/mt.2014.7","article-title":"A pRb-responsive, RGD-modified, and hyaluronidase-armed canine oncolytic adenovirus for application in veterinary oncology","volume":"22","author":"Laborda","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Delgado-Bonet, P., Tomeo-Mart\u00edn, B.D., Delgado-Bonet, B., Sard\u00f3n-Ruiz, D., Torrado-Carvajal, A., Mateo, I., and Peris\u00e9-Barrios, A.J. (2022). Intracranial Virotherapy for a Canine Hemangioma. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911677"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1158\/0008-5472.CAN-17-3754","article-title":"Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy","volume":"78","author":"Cejalvo","year":"2018","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Matveeva, O.V., Guo, Z.S., Shabalina, S.A., and Chumakov, P.M. (2015). Oncolysis by paramyxoviruses: Multiple mechanisms contribute to therapeutic efficiency. Mol. Ther. Oncolytics, 2.","DOI":"10.1038\/mto.2015.11"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Matveeva, O.V., and Shabalina, S.A. (2020). Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy. Cancers, 12.","DOI":"10.3390\/cancers12123659"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Zimmermann, M., Armeanu-Ebinger, S., Bossow, S., Lampe, J., Smirnow, I., Schenk, A., Lange, S., Weiss, T.S., Neubert, W., and Lauer, U.M. (2014). Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090508"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10555-019-09811-7","article-title":"Cell surface-anchored serine proteases in cancer progression and metastasis","volume":"38","author":"Martin","year":"2019","journal-title":"Cancer Metastasis Rev."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Ilyinskaya, G.V., Mukhina, E.V., Soboleva, A.V., Matveeva, O.V., and Chumakov, P.M. (2018). Oncolytic Sendai Virus Therapy of Canine Mast Cell Tumors (A Pilot Study). Front. Vet. Sci., 5.","DOI":"10.3389\/fvets.2018.00116"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez, D., Cesarman-Maus, G., Romero, L., S\u00e1nchez-Verin, R., Vail, D., Guadarrama, M., Pelayo, R., Sarmiento-Silva, R.E., and Lizano, M. (2024). The NDV-MLS as an Immunotherapeutic Strategy for Breast Cancer: Proof of Concept in Female Companion Dogs with Spontaneous Mammary Cancer. Viruses, 16.","DOI":"10.3390\/v16030372"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Rossmeisl, J.H., King, J.N., Robertson, J.L., Weger-Lucarelli, J., and Elankumaran, S. (2024). Phase I\/II Trial of Urokinase Plasminogen Activator-Targeted Oncolytic Newcastle Disease Virus for Canine Intracranial Tumors. Cancers, 16.","DOI":"10.3390\/cancers16030564"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): A Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet. Comp. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s12276-023-00977-3","article-title":"Comparative oncology: Overcoming human cancer through companion animal studies","volume":"55","author":"Oh","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.micpath.2003.07.003","article-title":"Role of fusion protein cleavage site in the virulence of Newcastle disease virus","volume":"36","author":"Panda","year":"2004","journal-title":"Microb. Pathog."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Schiffman, J.D., and Breen, M. (2015). Comparative oncology: What dogs and other species can teach us about humans with cancer. Philos. Trans. R. Soc. Lond. B Biol. Sci., 370.","DOI":"10.1098\/rstb.2014.0231"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.molmed.2011.02.004","article-title":"Dog models of naturally occurring cancer","volume":"17","author":"Rowell","year":"2011","journal-title":"Trends Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Sarkisova, V.A., Dalina, A.A., Neymysheva, D.O., Zenov, M.A., Ilyinskaya, G.V., and Chumakov, P.M. (2025). Cell Carriers for Oncolytic Virus Delivery: Prospects for Systemic Administration. Cancers, 17.","DOI":"10.20944\/preprints202506.1079.v1"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Park, J.S., Lee, M.E., Kim, J., Oh, K., Lee, N., Jung, M., Jang, W.S., and Ham, W.S. (2024). PD-1 inhibitor plus oncolytic vaccinia virus is a safe and effective treatment option for metastatic renal cell carcinoma. Cancer Cell Int., 24.","DOI":"10.1186\/s12935-024-03238-z"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Tran, T.Q., Grein, J., Selman, M., Annamalai, L., Yearley, J.H., Blumenschein, W.M., Sadekova, S., Chackerian, A.A., Phan, U., and Wong, J.C. (2024). Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer. Mol. Ther. Oncol., 32.","DOI":"10.1016\/j.omton.2024.200807"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/OV.S145532","article-title":"Oncolytic virus and PD-1\/PD-L1 blockade combination therapy","volume":"7","author":"Chen","year":"2018","journal-title":"Oncolytic Virother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000535418","article-title":"Oncolytic Activity of Canine Distemper Virus in Human Ductal Breast Carcinoma Cells","volume":"47","author":"Jhala","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/vco.12466","article-title":"Oncolytic activity of canine distemper virus in canine mammary tubular adenocarcinoma cells","volume":"17","author":"Li","year":"2019","journal-title":"Vet. Comp. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1111\/jvim.17080","article-title":"Safety and biologic activity of a canine anti-CD20 monoclonal antibody in dogs with diffuse large B-cell lymphoma","volume":"38","author":"McLinden","year":"2024","journal-title":"J. Vet. Intern. Med."},{"key":"ref_110","unstructured":"(2026, April 01). ONCEPT\u00ae. Canine Melanoma Vaccine, DNA. Available online: https:\/\/animalhealth.boehringer-ingelheim.com\/pets\/canine\/products\/therapeutics\/oncept."},{"key":"ref_111","unstructured":"(2026, April 01). ELIAS Cancer Immunotherapy (ECI\u00ae). Available online: https:\/\/eliasanimalhealth.com\/elias-cancer-immunotherapy."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/5\/518\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:20:42Z","timestamp":1777695642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/18\/5\/518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":111,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["v18050518"],"URL":"https:\/\/doi.org\/10.3390\/v18050518","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}